Article

You have full text access to this OnlineOpen article

Protease inhibitors derived from elafin and SLPI and engineered to have enhanced specificity towards neutrophil serine proteases

  1. Marie-Louise Zani,
  2. Kévin Baranger,
  3. Nicolas Guyot†,
  4. Sandrine Dallet-Choisy,
  5. Thierry Moreau*

Article first published online: 12 JAN 2009

DOI: 10.1002/pro.64

Issue

Protein Science

Protein Science

Volume 18, Issue 3, pages 579–594, March 2009

Additional Information

How to Cite

Zani, M.-L., Baranger, K., Guyot, N., Dallet-Choisy, S. and Moreau, T. (2009), Protease inhibitors derived from elafin and SLPI and engineered to have enhanced specificity towards neutrophil serine proteases. Protein Science, 18: 579–594. doi: 10.1002/pro.64

Author Information

  1. Inserm U618 “Protéases et Vectorisation Pulmonaires”, IFR 135 Imagerie Fonctionnelle, University of Tours, France

  1. †

    EA 4303 Immunité et Inflammation de l'Epithélium Respiratoire, IFR 53, University of Reims, France

*Inserm U618 “Protéases et Vectorisation Pulmonaires”, Faculté de Médecine, 10 Bd Tonnellé 37032 Tours Cedex France

Publication History

  1. Issue published online: 23 FEB 2009
  2. Article first published online: 12 JAN 2009
  3. Accepted manuscript online: 12 JAN 2009 12:00AM EST
  4. Manuscript Accepted: 12 DEC 2008
  5. Manuscript Revised: 10 DEC 2008
  6. Manuscript Received: 21 OCT 2008

Funded by

  • French National Research Agency. Grant Number: Project ANR-07-PHYSIO-029-01
  • Conseil Régional du Centre (Project INFINHI)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (946K)

References

  • 1
    Shapiro SD ( 2002) Proteinases in chronic obstructive pulmonary disease. Biochem Soc Trans 30: 98–102.
  • 2
    Shapiro SD ( 2003) Proteolysis in the lung. Eur Respir J Suppl 44: 30s–32s.
  • 3
    Owen CA ( 2008) Roles for proteinases in the pathogenesis of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 3: 253–268.
  • 4
    Voynow JA, Fischer BM, Zheng S ( 2008) Proteases and cystic fibrosis. Int J Biochem Cell Biol 40: 1238–1245.
  • 5
    Ganz T, Selsted ME, Szklarek D, Harwig SS, Daher K, Bainton DF, Lehrer RI ( 1985) Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest 76: 1427–1435.
  • 6
    Faurschou M, Borregaard N ( 2003) Neutrophil granules and secretory vesicles in inflammation. Microbes Infect 5: 1317–1327.
  • 7
    Owen CA, Campbell EJ ( 1999) The cell biology of leukocyte-mediated proteolysis. J Leukoc Biol 65: 137–150.
  • 8
    Owen CA ( 2008) Leukocyte cell surface proteinases: regulation of expression, functions, and mechanisms of surface localization. Int J Biochem Cell Biol 40: 1246–1272.
  • 9
    Witko-Sarsat V, Rieu P, Descamps-Latscha B, Lesavre P, Halbwachs-Mecarelli L ( 2000) Neutrophils: molecules, functions and pathophysiological aspects. Lab Invest 80: 617–653.
  • 10
    Wiedow O, Meyer-Hoffert U ( 2005) Neutrophil serine proteases: potential key regulators of cell signalling during inflammation. J Intern Med 257: 319–328.
    Direct Link:
  • 11
    Nathan C ( 2006) Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 6: 173–182.
  • 12
    Pham CT ( 2008) Neutrophil serine proteases fine-tune the inflammatory response. Int J Biochem Cell Biol 40: 1317–1333.
  • 13
    Korkmaz B, Poutrain P, Hazouard E, de Monte M, Attucci S, Gauthier FL ( 2005) Competition between elastase and related proteases from human neutrophil for binding to alpha1-protease inhibitor. Am J Respir Cell Mol Biol 32: 553–559.
  • 14
    Chang WS, Lomas DA ( 1998) Latent alpha1-antichymotrypsin. A molecular explanation for the inactivation of alpha1-antichymotrypsin in chronic bronchitis and emphysema. J Biol Chem 273: 3695–3701.
  • 15
    Moreau T, Baranger K, Dade S, Dallet-Choisy S, Guyot N, Zani ML ( 2008) Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family. Biochimie 90: 284–295.
  • 16
    Vogelmeier C, Hubbard RC, Fells GA, Schnebli HP, Thompson RC, Fritz H, Crystal RG ( 1991) Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor. J Clin Invest 87: 482–488.
  • 17
    Guyot N, Zani ML, Berger P, Dallet-Choisy S, Moreau T ( 2005) Proteolytic susceptibility of the serine protease inhibitor trappin-2 (pre-elafin): evidence for tryptase-mediated generation of elafin. Biol Chem 386: 391–399.
  • 18
    Guyot N, Zani ML, Maurel MC, Dallet-Choisy S, Moreau T ( 2005) Elafin and its precursor trappin-2 still inhibit neutrophil serine proteinases when they are covalently bound to extracellular matrix proteins by tissue transglutaminase. Biochemistry 44: 15610–15618.
  • 19
    Laskowski M,Jr,Kato I ( 1980) Protein inhibitors of proteinases. Annu Rev Biochem 49: 593–626.
  • 20
    Tremblay GM, Vachon E, Larouche C, Bourbonnais Y ( 2002) Inhibition of human neutrophil elastase-induced acute lung injury in hamsters by recombinant human pre-elafin (trappin-2). Chest 121: 582–588.
  • 21
    Simpson AJ, Wallace WA, Marsden ME, Govan JR, Porteous DJ, Haslett C Sallenave JM ( 2001) Adenoviral augmentation of elafin protects the lung against acute injury mediated by activated neutrophils and bacterial infection. J Immunol 167: 1778–1786.
  • 22
    Vachon E, Bourbonnais Y, Bingle CD, Rowe SJ, Janelle MF, Tremblay GM ( 2002) Anti-inflammatory effect of pre-elafin in lipopolysaccharide-induced acute lung inflammation. Biol Chem 383: 1249–1256.
  • 23
    Janelle MF, Doucet A, Bouchard D, Bourbonnais Y, Tremblay GM ( 2006) Increased local levels of granulocyte colony-stimulating factor are associated with the beneficial effect of pre-elafin (SKALP/trappin-2/WAP3) in experimental emphysema. Biol Chem 387: 903–909.
  • 24
    Doucet A, Bouchard D, Janelle MF, Bellemare A, Gagne S, Tremblay GM, Bourbonnais Y ( 2007) Characterization of human pre-elafin mutants: full antipeptidase activity is essential to preserve lung tissue integrity in experimental emphysema. Biochem J 405: 455–463.
  • 25
    Sallenave JM, Cunningham GA, James RM, McLachlan G, Haslett C ( 2003) Regulation of pulmonary and systemic bacterial lipopolysaccharide responses in transgenic mice expressing human elafin. Infect Immun 71: 3766–3774.
  • 26
    Henriksen PA, Hitt M, Xing Z, Wang J, Haslett C, Riemersma RA, Webb DJ, Kotelevtsev YV, Sallenave JM ( 2004) Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli. J Immunol 172: 4535–4544.
  • 27
    Butler MW, Robertson I, Greene CM, O'Neill SJ, Taggart CC, McElvaney NG ( 2006) Elafin prevents lipopolysaccharide-induced AP-1 and NF-kappaB activation via an effect on the ubiquitin-proteasome pathway. J Biol Chem 281: 34730–34735.
  • 28
    Baranger K, Zani ML, Chandenier J, Dallet-Choisy S, Moreau T ( 2008) The antibacterial and antifungal properties of trappin-2 (pre-elafin) do not depend on its protease inhibitory function. FEBS J 275: 2008–2020.
    Direct Link:
  • 29
    Zani ML, Nobar SM, Lacour SA, Lemoine S, Boudier C, Bieth JG, Moreau T ( 2004) Kinetics of the inhibition of neutrophil proteinases by recombinant elafin and pre-elafin (trappin-2) expressed in Pichia pastoris. Eur J Biochem 271: 2370–2378.
    Direct Link:
  • 30
    Sallenave JM, Si Tahar M, Cox G, Chignard M, Gauldie J ( 1997) Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils. J Leukoc Biol 61: 695–702.
  • 31
    Sallenave JM, Shulmann J, Crossley J, Jordana M, Gauldie J ( 1994) Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am J Respir Cell Mol Biol 11: 733–741.
  • 32
    Kramps JA, van Twisk C, Appelhans H, Meckelein B, Nikiforov T, Dijkman JH ( 1990) Proteinase inhibitory activities of antileukoprotease are represented by its second COOH-terminal domain. Biochim Biophys Acta 1038: 178–185.
  • 33
    Van-Seuningen I, Davril M ( 1991) Separation of the two domains of human mucus proteinase inhibitor: inhibitory activity is only located in the carboxy-terminal domain. Biochem Biophys Res Commun 179: 1587–1592.
  • 34
    Grutter MG, Fendrich G, Huber R, Bode W ( 1988) The 2.5 Å X-ray crystal structure of the acid-stable proteinase inhibitor from human mucous secretions analysed in its complex with bovine alpha-chymotrypsin. EMBO J 7: 345–351.
  • 35
    Nobar SM, Zani ML, Boudier C, Moreau T, Bieth JG ( 2005) Oxidized elafin and trappin poorly inhibit the elastolytic activity of neutrophil elastase and proteinase 3. FEBS J 272: 5883–5893.
    Direct Link:
  • 36
    Campbell EJ, Campbell MA, Owen CA ( 2000) Bioactive proteinase 3 on the cell surface of human neutrophils: quantification, catalytic activity, and susceptibility to inhibition. J Immunol 165: 3366–3374.
  • 37
    Korkmaz B, Attucci S, Jourdan ML, Juliano L, Gauthier F ( 2005) Inhibition of neutrophil elastase by alpha1-protease inhibitor at the surface of human polymorphonuclear neutrophils. J Immunol 175: 3329–3338.
  • 38
    Bieth JG ( 1995) Theoretical and practical aspects of proteinase inhibition kinetics. Methods Enzymol 248: 59–84.
  • 39
    Schalkwijk J, Wiedow O, Hirose S ( 1999) The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core. Biochem J 340: 569–577.
  • 40
    Sheinerman FB, Norel R, Honig B ( 2000) Electrostatic aspects of protein-protein interactions. Curr Opin Struct Biol 10: 153–159.
  • 41
    Norel R, Sheinerman F, Petrey D, Honig B ( 2001) Electrostatic contributions to protein-protein interactions: fast energetic filters for docking and their physical basis. Protein Sci 10: 2147–2161.
    Direct Link:
  • 42
    Sheinerman FB, Honig B ( 2002) On the role of electrostatic interactions in the design of protein-protein interfaces. J Mol Biol 318: 161–177.
  • 43
    Braden BC, Poljak RJ ( 1995) Structural features of the reactions between antibodies and protein antigens. FASEB J 9: 9–16.
  • 44
    Epa VC, Colman PM ( 2001) Shape and electrostatic complementarity at viral antigen-antibody complexes. Curr Top Microbiol Immunol 260: 45–53.
  • 45
    Villoutreix BO, Getzoff ED, Griffin JH ( 1994) A structural model for the prostate disease marker, human prostate-specific antigen. Protein Sci 3: 2033–2044.
    Direct Link:
  • 46
    Moreau T, Gauthier F ( 1996) Homology modelling of rat kallikrein rK9, a member of the tissue kallikrein family: implications for substrate specificity and inhibitor binding. Protein Eng 9: 987–995.
  • 47
    Koizumi M, Fujino A, Fukushima K, Kamimura T, Takimoto-Kamimura M ( 2008) Complex of human neutrophil elastase with 1/2SLPI. J Synchrotron Radiat 15: 308–311.
    Direct Link:
  • 48
    Dundas J, Ouyang Z, Tseng J, Binkowski A, Turpaz Y, Liang J ( 2006) CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucleic Acids Res 34: W116–118.
  • 49
    Otlewski J, Jaskolski M, Buczek O, Cierpicki T, Czapinska H, Krowarsch D, Smalas AO, Stachowiak D, Szpineta A, Dadlez M ( 2001) Structure-function relationship of serine protease-protein inhibitor interaction. Acta Biochim Pol 48: 419–428.
  • 50
    Buczek O, Koscielska-Kasprzak K, Krowarsch D, Dadlez M, Otlewski J ( 2002) Analysis of serine proteinase-inhibitor interaction by alanine shaving. Protein Sci 11: 806–819.
    Direct Link:
  • 51
    Bieth JG ( 1984) In vivo significance of kinetic constants of protein proteinase inhibitors. Biochem Med 32: 387–397.
  • 52
    Korkmaz B, Hajjar E, Kalupov T, Reuter N, Brillard-Bourdet M, Moreau T, Juliano L, Gauthier F ( 2007) Influence of charge distribution at the active site surface on the substrate specificity of human neutrophil protease 3 and elastase. A kinetic and molecular modeling analysis. J Biol Chem 282: 1989–1997.
  • 53
    Owen CA, Campbell EJ ( 1998) Angiotensin II generation at the cell surface of activated neutrophils: novel cathepsin G-mediated catalytic activity that is resistant to inhibition. J Immunol 160: 1436–1443.
  • 54
    Rice WG, Weiss SJ ( 1990) Regulation of proteolysis at the neutrophil-substrate interface by secretory leukoprotease inhibitor. Science 249: 178–181.
  • 55
    Nara K, Ito S, Ito T, Suzuki Y, Ghoneim MA, Tachibana S, Hirose S ( 1994) Elastase inhibitor elafin is a new type of proteinase inhibitor which has a transglutaminase-mediated anchoring sequence termed “cementoin”. J Biochem 115: 441–448.
  • 56
    Yoshida N, Egami H, Yamashita J, Takai E, Tamori Y, Fujino N, Kitaoka M, Schalkwijk J, Ogawa M ( 2002) Immunohistochemical expression of SKALP/elafin in squamous cell carcinoma of human lung. Oncol Rep 9: 495–501.
  • 57
    Muto J, Kuroda K, Wachi H, Hirose S, Tajima S ( 2007) Accumulation of elafin in actinic elastosis of sun-damaged skin: elafin binds to elastin and prevents elastolytic degradation. J Invest Dermatol 127: 1358–1366.
  • 58
    Lorand L, Graham RM ( 2003) Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 4: 140–156.
  • 59
    Maiuri L, Luciani A, Giardino I, Raia V, Villella VR, D'Apolito M, Pettoello-Mantovani M, Guido S, Ciacci C, Cimmino M, Cexus ON, Londei M, Quaratino S ( 2008) Tissue transglutaminase activation modulates inflammation in cystic fibrosis via PPARgamma down-regulation. J Immunol 180: 7697–7705.
  • 60
    Steinert PM, Marekov LN ( 1995) The proteins elafin, filaggrin, keratin intermediate filaments, loricrin, and small proline-rich proteins 1 and 2 are isodipeptide cross-linked components of the human epidermal cornified cell envelope. J Biol Chem 270: 17702–17711.
  • 61
    Rao NV, Wehner NG, Marshall BC, Sturrock AB, Huecksteadt TP, Rao GV, Gray BH, Hoidal JR ( 1991) Proteinase-3 (PR-3): a polymorphonuclear leukocyte serine proteinase. Ann NY Acad Sci 624: 60–68.
    Direct Link:
  • 62
    Boudier C, Bieth JG ( 1992) The proteinase: mucus proteinase inhibitor binding stoichiometry. J Biol Chem 267: 4370–4375.
  • 63
    Schagger H, von Jagow G ( 1987) Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem 166: 368–379.
  • 64
    Korkmaz B, Attucci S, Moreau T, Godat E, Juliano L, Gauthier F ( 2004) Design and use of highly specific substrates of neutrophil elastase and proteinase 3. Am J Respir Cell Mol Biol 30: 801–807.
  • 65
    Attucci S, Korkmaz B, Juliano L, Hazouard E, Girardin C, Brillard-Bourdet M, Réhault S, Anthonioz P, Gauthier F ( 2002) Measurement of free and membrane-bound cathepsin G in human neutrophils using new sensitive fluorogenic substrates. Biochem J 366: 965–970.
  • 66
    Sharp KA, Honig B ( 1990) Electrostatic interactions in macromolecules: theory and applications. Annu Rev Biophys Biophys Chem 19: 301–332.
View Full Article (HTML) Get PDF (946K)